Vertex: life after cystic fibrosis
Cystic fibrosis still brings in 96% of sales. A pain pill, a gene therapy, a kidney drug decision on November 30 and a $10 billion acquisition are meant to change that. An Amber first look.
Oct 12, 2026
Cystic fibrosis still brings in 96% of sales. A pain pill, a gene therapy, a kidney drug decision on November 30 and a $10 billion acquisition are meant to change that. An Amber first look.
Oct 12, 2026
Haverhill Financial Research publishes general, impersonal financial research for educational purposes only. Nothing on this site or in our newsletters is personalized investment advice or a recommendation to buy or sell any security for your specific situation. Do your own research and consider consulting a licensed professional before investing. Authors may hold positions in securities discussed; positions are disclosed in each issue.
Questions or customer inquiries: [email protected]
© 2026 Haverhill Financial Research